Filing Details
- Accession Number:
- 0001787306-24-000159
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-19 19:52:52
- Reporting Period:
- 2024-11-18
- Accepted Time:
- 2024-11-19 19:52:52
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1787306 | Arcutis Biotherapeutics Inc. | ARQT | Pharmaceutical Preparations (2834) | 812974255 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1798679 | Masaru Matsuda | C/O Arcutis Biotherapeutics, Inc. 3027 Townsgate Road, Suite 300 Westlake Village CA 91361 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-11-18 | 4,875 | $0.00 | 183,148 | No | 4 | A | Direct | |
Common Stock | Disposition | 2024-11-19 | 1,775 | $9.68 | 181,373 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- Represents the vesting of performance stock units ("PSUs") initially granted on January 3, 2022, that were subject to a performance-based vesting condition. The vesting condition was certified as satisfied on November 18, 2022. The PSUs vest 25% per year on each anniversary of the certification date, subject to the Reporting Person's continued service to the Issuer on such vesting date.
- Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable tax withholdings.
- The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $9.22 to $10.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.